

RECEIVED

SEP 20 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


TECH CENTER 1600/2900

In re application of:

Dario NERI et al.

Serial No.: 09/512,082

Filed: February 24, 2000



Group Art Unit: 1645

Examiner: V. Portner

#5B 9/23/00
T. Gray

For: SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY,
CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD
FOR TREATMENT OF ANGIOGENESIS

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated August 21, 2000, please amend the above-identified application as indicated below and consider the Remarks which follow:

IN THE SPECIFICATION:

After the title, please add:

RELATED APPLICATIONS:

B' --This application is a Continuation-in-Part of U.S. application no: 09/075,338, filed May 11, 1998, which is a Continuation-in-Part of U.S. application no: 09/300,425, filed April 28, 1999, both of which are herein incorporated by reference in their entirety.--

IN THE CLAIMS:

Please cancel claims 1-13 and 18 without prejudice or disclaimer.

REMARKS

Small Entity Status

Please note that this application is no longer entitled to Small Entity Status.

Oath/Declaration

Applicants wish to clarify that the claims to priority to two ancestor U.S. applications should have been made under 35 U.S.C. 120. Claiming them under 35 U.S.C. 119 was incorrect. A corrected Supplemental Declaration will be filed shortly.

Sequence Listing

A Sequence Listing was filed on September 1, 2000.

Objection to the Specification

Applicant could find nothing in the M.P.E.P. that indicates reference to a world wide web (www) site is improper, and therefore have not amended the specification on Page 15 as suggested in the Office Action.

The restriction requirement

Applicants elect the claims of Group IV (claims 20-34), with traverse. The traverse is based, in part, on the fact that the subject matter of the claims of Group IV is related to that of the other claims in the application. Therefore, a search of all the claims in the application would not be an undue burden on the Examiner. If the search and examination can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions. See, e.g., M.P.E.P. 803.

Applicants note an apparent error in Group III, *i.e.*, claims 25 and 27 are also included in Group IV. Applicants request that the only remaining claim in Group III, claim 19, also be examined with the elected claims, because the subject matter (at least as it relates to a method of therapy) overlaps with that of the claims of Group IV.

RECEIVED

SEP 20 2000

TECH CENTER 1600/2000

Since claims 1-13 and 18 are being examined in ancestor application no: 09/075,338,
these claims have been canceled without prejudice in the instant application.

Respectfully submitted,

Nancy Axelrod (Reg. No. 44,014) for

Richard M. Lebovitz (Reg. No. 37,067)
Attorneys for Applicants

Nancy Axelrod

Nancy J. Axelrod (Reg. No. 44,014)
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
(703) 812-5304
E-mail address: axelrod@mwzb.com

Filed: September 18, 2000

RML/NJA/lvb
K:\PAT\Sch\1733p2\reply 9-18-00.wpd